Nexalin Technology, Inc. NXL
Regular-session close
After hours · Nov 19, 5:58 PM ET
- YTD
- -91.70%
- 1 year
- -95.59%
5D +0.04 (+2.58%)
- Market cap
- 1.72M
- Revenue (ttm)
- 150.16K
- EPS (ttm)
- -13.21
- Shares out
- 12.86M
- Forward P/E
- -6.39
- YTD return
- -91.70%
- 1-year return
- -95.59%
- Volume
- 9.97K
- Avg volume
- 1.04M
- Open
- 1.40
- Previous close
- 1.48
- Day's range
- 1.39 – 1.48
- 52-week range
- 1.39 – 32.70
- Beta
- 3.57
Key statistics
- 50-day average
- 3.12
- 200-day average
- 1.64
- Enterprise value
- 39.38M
- Price / sales
- 224.41
- Price / book
- 6.08
- Revenue growth
- -24.50%
- Free cash flow
- -1.75M
- Total cash
- 848.80K
- Return on equity
- -202.23%
- Short % of float
- 1.03%
Fundamental scorecard
4 of 25 checks passed on NXL’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | 0.00 | -0.23 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -0.17 | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | -0.14 | — | — |
| Mar 27, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -0.31 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Maxim Group | down | Buy | Hold |
| Oct 9, 2024 | Maxim Group | init | — | Buy |
About Nexalin Technology, Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- nexalin.com
News
Nexalin Technology Announces Publication Of Fourth Peer-Reviewed Article Reporting Results From Clinical Research On 15 mA DIFS Technology In Alzheimer's Disease
Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease
Nuix Launches Agentic AI in Nuix Neo with Audit Trail Built In
Nexalin Technology (NASDAQ:NXL) vs. IceCure Medical (NASDAQ:ICCM) Financial Analysis
Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
Critical Survey: Enovis (NYSE:ENOV) vs. Nexalin Technology (NASDAQ:NXL)
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy
LogicMark (OTCMKTS:LGMKD) vs. Nexalin Technology (NASDAQ:NXL) Head to Head Comparison
Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study
Your note
Sign in to keep a note on NXL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERNHARD LESLIE | Director | Stock Award(Grant) | Sep 29, 2024 | 49,838 |
| ELSON MARILYN | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Sep 29, 2024 | 1,535,240 |
| HU BENJAMIN | Director | Stock Award(Grant) | Sep 29, 2024 | 340,636 |
| OWENS DAVID | Officer and Director | Purchase | Oct 27, 2024 | 148,293 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 0.80% | 102,900 | 269.60K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.61% | 78,697 | 206.19K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.45% | 58,185 | 152.44K | Sep 29, 2024 |
| CVI Holdings, LLC | 0.43% | 55,462 | 145.31K | Jun 29, 2024 |
| Susquehanna International Group, LLP | 0.33% | 42,383 | 111.04K | Sep 29, 2024 |
| Vanguard Group Inc | 0.25% | 31,780 | 83.26K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.41% | 52,237 | 136.86K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.25% | 31,780 | 83.26K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 17,079 | 44.75K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 12,296 | 32.22K | Oct 30, 2024 |
